Elevance Health shows a credible medium-term recovery story, supported by valuation and cash flow, but Medicaid pressure and earnings volatility keep the stock at Hold. The report highlights improving Medicare Advantage economics, Carelon expansion, and a 2027 EPS growth target, offset by near-term execution risk.
Investment thesis: Elevance Health (ELV) is a diversified managed-care platform with a credible medium-term recovery path, but the stock still carries meaningful execution risk. The company generated $199.1B of revenue in 2025, held $10.2B of cash at June 30, 2026, and raised 2026 adjusted EPS guidance to at least $27.00 after Q2 adjusted EPS of $7.45. Those figures support a constructive view of the business. The counterweight is equally concrete: 2025 earnings fell 13.1% year over year, revenue growth in the valuation data was 1.4%, and Medicaid carried a full-year operating margin outlook of approximately -1.75%.
The central recovery lever is operating execution. Elevance is repositioning Medicare Advantage, managing Medicaid markets more selectively, and expanding Carelon's pharmacy, behavioral health, home-based, and analytics capabilities. Management also stated that it expects at least 12% adjusted EPS growth in 2027 from the ending 2026 baseline. The plan has substance, but the earnings base must first absorb elevated medical utilization, higher government-program costs, and one-time investment spending.
For a moderate-risk investor, ELV fits better as a recovery and quality-compounder candidate than as a high-growth holding. The forward P/E of 13.7x, PEG ratio of 1.3, and reported free-cash-flow yield of 5.9% provide valuation support. A Hold recommendation reflects the balance between that support and the current earnings volatility.
Elevance Health (ELV), formerly Anthem, is a U.S.-focused health benefits company based in Indianapolis. The company had 96,129 employees and operated through Health Benefits, CarelonRx, Carelon Services, and Corporate & Other at the 2025 10-K reporting date. Its brands include Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon.
The operating model combines risk-bearing insurance with fee-based healthcare services. Health Benefits serves employer groups, individual customers, Medicare, Medicaid, BlueCard members, and Federal Employee Program members. Carelon adds pharmacy services, specialty pharmacy, behavioral health, care delivery, utilization management, payment integrity, analytics, and virtual care.
Elevance reported 44.9 million medical members at June 30, 2026. Q2 operating revenue reached $50.5B in the financial statements and $49.8B in the earnings release context, with the release reporting 0.8% year-over-year growth. The difference reflects period and presentation conventions, while both figures point to a very large, recurring revenue base.
Health Benefits remains the economic anchor. The 2025 segment data lists $167.1B of Health Benefits revenue, or 84.8% of the reported segment total. The business includes commercial risk-based plans, commercial fee-based services, individual ACA products, Medicare Advantage, Medicaid, BlueCard administration, dental, vision, stop-loss, and supplemental products.
The segment is managing different operating conditions across product lines. Medicare Advantage benefited from disciplined plan design, a more focused D-SNP and HMO mix, and favorable claims experience. Management supports an operating margin of at least 2% for 2026. Medicaid remains the weak spot, with elevated behavioral health, specialty pharmacy, outpatient surgery, and emergency department utilization.
The 2025 segment data lists $71.7B of Carelon Services revenue, or 36.4% of the reported segment total. CarelonRx supplies claims adjudication, formulary management, pharmacy networks, rebate administration, home delivery, specialty pharmacy, and ambulatory infusion services. Carelon Services adds behavioral health, Carelon Health, CareBridge, provider enablement, virtual care, data, and clinical analytics.
Carelon's strategic value is larger than its immediate earnings contribution. It gives ELV internal tools to control medical costs and external services to sell beyond the owned health plans. Q4 2025 Carelon operating revenue was reported at $18.7B, up 27% year over year, while Q2 2026 management described near-term Carelon Services earnings as affected by platform investment and newer risk-based programs.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
ELV's flagship offering is the integrated health benefits platform built around employer, government, and individual coverage. The product is not simply an insurance card. It combines provider networks, benefit design, pharmacy services, clinical programs, member engagement, and care coordination. That structure lets ELV compete on affordability and service rather than on premium price alone.
The Anthem Blue Cross and Blue Shield franchise remains especially important in commercial markets. ELV's BlueCard position allows members to use participating Blue Cross and Blue Shield provider networks outside the home state, while ELV performs claims pricing and administration for host members. The 2025 10-K identified 33 independent primary Blue Cross and Blue Shield licensees, giving the franchise broad employer-market reach.
Medicare Advantage is the most visible product-level recovery opportunity. About 59% of ELV's Medicare Advantage members were in plans rated at least 4.0 stars or equivalent for the 2026 ratings year, up from about 40% in the prior ratings cycle. That improvement supports quality bonus economics and strengthens the product's appeal, although the 2026 plan redesign also prioritizes sustainable margins over aggressive membership growth.
ELV's innovation program is centered on lowering total medical cost and reducing administrative friction. Management described AI-enabled capabilities that compress some medical-cost analysis from months into days. Sydney Health, Concierge Care, and proactive member engagement connect members with benefits guidance, scheduling, condition management, and care-gap support.
Health OS extends the technology strategy to providers. Management reported reductions in avoidable denials, documentation requests, and administrative friction in health systems where the workflows were deployed. The investment is strategically relevant because payer margins depend on accurate claims, timely clinical review, network discipline, and provider cooperation.
Carelon provides the more durable competitive advantage. CareBridge brings whole-health coordination into the home and management cited medical savings in the mid-teens for members served by the program. Behavioral health programs have delivered average cost savings of 10%. Those results give ELV measurable evidence that integrated services can support both member outcomes and insurance economics.
A managed-care company's operating chain runs through members, physicians, hospitals, pharmacies, claims systems, state agencies, and federal programs. ELV manages this chain through provider contracting, network design, utilization review, payment integrity, care management, pharmacy networks, and member service platforms. The 2025 10-K identifies provider pricing, medical management, risk adjustment, quality ratings, and operating efficiency as core drivers.
The pharmacy chain is strategically important but includes a material external dependency. CarelonRx provides the pharmacy platform, while core PBM functions are delegated to CVS Health (CVS) under a contract running through December 31, 2027, with a possible three-year extension. That arrangement gives ELV pharmacy scale without full internal ownership of every PBM function.
Operational cash flow was $1.9B in Q2 2026, and management raised full-year operating cash flow guidance to at least $6.0B. Days in claims payable were 45.4 at June 30, up 2.9 days year over year. The June quarter also included the timing of a Medicaid pass-through payment and a $342M initial CMS remittance, so cash flow quality requires attention to working-capital timing.
ELV operates in a large and expanding U.S. healthcare market. Industry estimates place the U.S. healthcare insurance market at $2.94T in 2025 and $4.41T by 2033. The U.S. healthcare payer-services market was estimated at $34.6B in 2025 and $56.8B by 2031, while the managed-care application within payer services was projected to grow at a 10.3% compound annual rate through 2031.
The market is shifting from basic claims administration toward integrated cost management. Care management solutions were estimated at $17.1B in 2025 and $60.1B by 2034. That growth profile favors ELV's investment in Carelon, Health OS, payment integrity, behavioral health, virtual care, and data-enabled clinical intervention.
Medicare Advantage remains a major channel. The Department of Health and Human Services reported that 55% of Medicare beneficiaries received care through Medicare Advantage in 2025. Scale, quality ratings, network breadth, and accurate medical-cost pricing will determine which plans convert that market opportunity into durable earnings.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
ELV serves several customer groups with different buying cycles and risk profiles. Employer customers purchase risk-based insurance or fee-based administration. Individuals purchase ACA products on or off public exchanges. Government customers include Medicare, Medicaid, and the Federal Employee Program. BlueCard members extend the company's reach through the broader Blue Cross and Blue Shield system.
The 2025 10-K reported that agencies of the U.S. government generated approximately 32% of consolidated revenue in 2025, up from 31% in 2024 and 29% in 2023. That exposure provides scale and recurring demand, but it also concentrates risk around CMS rules, state Medicaid rates, risk adjustment, and government procurement.
Customer needs are becoming more specific. Employers are seeking lower healthcare costs, easier navigation, behavioral health support, and digital engagement. Medicaid and Medicare members require complex care coordination. ELV's product mix and Carelon capabilities address those needs, while the 2026 expectation of at least 1 million individual ACA members gives the exchange business a measurable scale objective.
UnitedHealth Group (UNH) is the broadest direct competitor across insurance, pharmacy, care delivery, and analytics. CVS Health (CVS) combines Aetna with a large PBM and retail healthcare network. Cigna Group (CI) is particularly strong in commercial coverage and pharmacy services. Humana (HUM) is a major Medicare Advantage competitor, while Centene (CNC) and Molina Healthcare (MOH) are especially relevant in Medicaid and ACA markets.
ELV's position is balanced. It has broader diversification than Medicaid-heavy CNC or MOH and less Medicare Advantage concentration than HUM. Its Carelon platform gives it more services depth than a pure health-plan operator. UnitedHealth Group (UNH) retains greater vertical integration, while CVS Health (CVS) has deeper PBM and retail assets.
The competitive advantage is therefore operational rather than purely financial. ELV's local market presence, BlueCard reach, government-program experience, 44.9 million medical members, and improving Medicare Advantage star ratings create a strong base. The risk is that Carelon investment and government-program complexity consume the benefits of scale before the services platform reaches mature profitability.
ELV's macro exposure is primarily domestic policy exposure rather than foreign geopolitical exposure. The 2025 10-K stated that an immaterial amount of revenue came from outside the U.S. and Puerto Rico. Federal and state reimbursement decisions therefore matter more than overseas demand, currency, or supply-chain disruptions.
Medicaid is the clearest macro-policy pressure point. Management set a full-year Medicaid operating margin outlook of approximately -1.75%, cited elevated utilization, and stated that the company expects to exit additional Medicaid markets over the next 12 to 18 months where sustainable performance is not present. Favorable July 1 rate activity and improving rate alignment provide a defined recovery mechanism, but the 2026 margin trough remains material.
Medicare Advantage also faces regulatory sensitivity through risk adjustment, star ratings, benefit design, and CMS payment rules. On July 9, 2026, CMS confirmed that sanctions would not be imposed and the relevant matter was closed. That removes a specific operational overhang, although it does not eliminate broader reimbursement and compliance risk.
Technology regulation creates both cost and opportunity. CMS prior-authorization rules generally require certain API capabilities beginning in 2026, with broader API development and enhancement requirements beginning in 2027. ELV's Health OS and digital investment align with that direction, but compliance spending must produce measurable administrative and clinical returns.
Elevance held $10.2B of cash at June 30, 2026, giving it a solid liquidity cushion even as earnings remain choppy.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →2025 revenue reached $199.1B, but earnings still fell 13.1% year over year, underscoring the pressure from elevated medical costs.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management raised 2026 adjusted EPS guidance to at least $27.00 and expects at least 12% adjusted EPS growth in 2027 from that baseline.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →A 13.7x forward P/E, 1.3 PEG ratio, and 5.9% free-cash-flow yield suggest the stock is supported, but not obviously cheap.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s valuation framework points to $420 as fair value, with upside and downside bands stretching from $300 to $560.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Elevance Health (ELV) has the scale, membership, product breadth, and Carelon infrastructure to compound earnings after a difficult profitability period. The Q2 2026 guidance increase to at least $27.00 of adjusted EPS and at least $6.0B of operating cash flow provides tangible evidence that the recovery is progressing.
The investment case remains conditional on operating facts that management has already identified: Medicaid rate alignment, lower medical-cost pressure, disciplined Medicare Advantage pricing, and profitable Carelon scaling. The company has addressed the specific CMS sanctions matter, improved Medicare Advantage star-rating exposure, and expanded its cash-generation outlook, but 2025 earnings contraction and government-program volatility remain part of the risk profile.
A Hold rating is the disciplined middle ground. The business merits respect, the forward valuation is reasonable, and a better entry price would improve the risk-reward balance. The $420.00 fair value estimate gives the medium-term recovery credit without treating management's targets as accomplished facts.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Elevance didn't get punished for missing the quarter; it got punished because the market no longer trusts the quality of the beat. Raised guidance matters less when Medicaid costs are still rising, membership is slipping, and management is calling 2026 the low point for profitability.
Elevance Health is working through a Medicaid-driven margin reset, but Q2 results, raised guidance, and Carelon growth point to a resilient earnings recovery. The stock looks attractively valued for a large managed-care platform with scale, cash flow, and multiple growth levers.
Elevance Health beat EPS and revenue, but the stock drops as investors focus on Medicaid margin pressure, membership declines, and the quality of the upside. This deep-dive breaks down the quarter’s mix, guidance, Carelon integration, and why a clean beat still failed to win the market.